Home Blog Page 286

THE KILLERS ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI®

Millions of fans from across the world tuned in to watch the iconic rock band’s unmissable performance ahead of the showpiece fixture of the club football season.

BUDAPEST, Hungary, May 31, 2026 /PRNewswire/ — #PEPSIKICKOFFSHOW – Global superstars The Killers delivered an exceptional headline performance at the Puskás Aréna in Budapest, for this year’s UEFA Champions League Final Kick Off Show presented by Pepsi.

THE KILLERS headline the UEFA Champions League Final Kick Off Show presented by Pepsi at the Puskás Aréna in Budapest, via Getty Images.
THE KILLERS headline the UEFA Champions League Final Kick Off Show presented by Pepsi at the Puskás Aréna in Budapest, via Getty Images.

The UEFA Champions League Final Kick Off Show presented by Pepsi took place minutes before the football season’s biggest fixture between Arsenal FC and Paris St. Germain, with The Killers performing classic hits and stadium sized anthems including “When You Were Young”, “Human”, “All These Things That I’ve Done”, and “Mr Brightside”.

The band brought their iconic status to club football’s grandest stage, providing an unforgettable experience for the thousands in the stadium and the millions watching around the globe, uniting both football and music fans.

Since arriving on the world stage with their iconic 2004 debut album, Hot Fuss, The Killers have gone on to solidify their place as globally recognised rock icons of the 21st century. The band have sold over 35 million albums, including multiplatinum hits like ‘Mr. Brightside’, ‘When You Were Young’ and ‘Human’, and recently confirmed that they are working on their eighth studio album, with electrifying global performances also on the horizon.

Before kick-off, fans in-stadium and across global broadcast were surprised by Sir David Beckham appearing on screens asking fans: ‘ready to kick things off?’. As Beckham dropped a coin into a jukebox, setting a vinyl of The Killers in motion, the pitch was transformed into a neon lit spectacle, with bold visuals and choreography inspired by the band’s Las Vegas roots.

With a longstanding heritage in sport and music, Pepsi has presented the UEFA Champions League Final Kick Off Show since 2016, each year merging the worlds of football and music together to create a night of epic entertainment. The event encapsulates Pepsi’s multi-year global platform, Pepsi Football Nation, which celebrates football culture on and off the pitch, bringing fans across the globe closer to moments beyond the 90 minutes.

THE KILLERS headline the UEFA Champions League Final Kick Off Show presented by Pepsi at the Puskás Aréna in Budapest, via Getty Images.
THE KILLERS headline the UEFA Champions League Final Kick Off Show presented by Pepsi at the Puskás Aréna in Budapest, via Getty Images.

 

 

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet

CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company’s TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) in combination with pembrolizumab (KEYTRUDA®[1], MSD’s anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East Hospital, Tongji University (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).


Sac-TMT is designed with a unique, bifunctional linker and differentiated belotecan-derivative payload. The linker is conjugated via cysteine, which maximizes payload delivery to tumor cells both through its irreversible connection with the high-affinity and targeting anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a moderately toxic novel topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4.


In the OptiTROP-Lung05 study, a total of 413 patients were randomized (1:1) to receive either sac-TMT in combination with pembrolizumab or pembrolizumab monotherapy.


As of the data cutoff date (September 29, 2025), with a median follow‑up of 10.5 months, the study demonstrated that:

  • Progression-free survival (PFS) showed statistically significant and clinically meaningful benefit in sac-TMT plus pembrolizumab compared with pembrolizumab alone. The median PFS assessed by blinded independent central review (BICR) was not reached (NR) vs 5.7 months (HR=0.35; 95% CI: 0.26-0.47; p<0.0001). The 12-month PFS rate was 62.4% vs 29.0%.


  • Consistent benefit across prespecified subgroups: In patients with PD‑L1 TPS ≥50% and TPS 1–49%, the PFS HRs were 0.47 (95% CI: 0.29–0.77) and 0.28 (95% CI: 0.19–0.41), respectively. In patients with non‑squamous and squamous NSCLC, the PFS HRs were 0.28 (95% CI: 0.18–0.43) and 0.44 (95% CI: 0.29–0.66), respectively.



  • Overall survival (OS) was not yet mature but showed a positive trend: median OS was NR vs 14.5 months (HR = 0.55; 95% CI: 0.36–0.85). The 12‑month OS rate was 80.4% vs 68.9%.
  • The combination group showed improvements over pembrolizumab monotherapy group in objective response rate (ORR) (70.2% vs 42.0%), deep response rate (49.0% vs 25.9%), and 12-month duration of response rate (77.7% vs 59.4%).


The incidence of grade ≥3 treatment-emergent adverse events (TEAEs) was higher in the combination group, primarily driven by the expected hematologic adverse events of sac-TMT. Incidence of discontinuation of pembrolizumab due to TEAEs was similar in both groups. No sac-TMT-related deaths occurred. Adverse events of special interest (AEOSIs) were consistent with the known safety profiles of each individual agent, and no new safety signals were identified.

The interim analysis results show that sac-TMT plus pembrolizumab significantly prolonged PFS and reduced the risk of disease progression or death compared with pembrolizumab alone, with consistent PFS benefits observed across all prespecified subgroups (including PD‑L1 expression levels and histological subtypes). A positive trend in OS was also observed. Furthermore, the overall safety profile of sac-TMT in combination with pembrolizumab was manageable, consistent with the established safety profiles of sac-TMT alone or pembrolizumab alone.

Notably, the findings of OptiTROP-Lung05 have been simultaneously published in The Lancet(Impact Factor=88.5), indicating that its clinical and academic value has received dual recognition from a leading international academic conference and an authoritative journal.


Professor Caicun Zhou, the national leading principal investigator from Shanghai East Hospital, Tongji University, said: “The positive results of the OptiTROP‑Lung05 study are encouraging. The study not only supports the application of sac‑TMT in an earlier-line setting for lung cancer, but also provides evidence of the ‘ADC+IO’ synergistic strategy being evaluated in the first-line setting for PD‑L1‑positive advanced NSCLC, potentially bringing a new option to a broad population of patients with lung cancer.”

[1] KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About sac-TMT(佳泰莱®)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the National Medical Products Administration (NMPA).

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO

CHENGDU, China, May 30, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”, 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company’s next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People’s Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.


The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.



The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.


In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.



Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).


Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.

The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.

Professor Qing Zhou, principal investigator from Guangdong Provincial People’s Hospital, said: “From the first presentation of Phase I data at ASCO 2023 to today’s pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients.”

[1] Trade name to be approved by NMPA.

About lunbotinib fumarate (A400/EP0031, 宁泰莱®)

Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.

In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

Duke-NUS graduates biggest class yet, with new doctors drawn from business, engineering and the humanities

At his first graduation as Dean, Patrick Tan presides over a record class of 135 graduates, with Guest of Honour Mdm Rahayu Mahzam and keynote speaker Dr Robert Califf

SINGAPORE, May 30, 2026 /PRNewswire/ — From engineers and business graduates to literature and communications majors, Duke-NUS Medical School’s largest graduating class to date reflects the widening range of backgrounds now flowing into medicine in Singapore. A total of 135 graduates crossed the stage on Saturday, including 78 new doctors from the MD programme.

Mdm Rahayu Mahzam with graduates from the Duke-NUS Medical School Class of 2026 and leaders from Duke-NUS, Duke University, NUS and SingHealth // Photo credit: Duke-NUS Medical School
Mdm Rahayu Mahzam with graduates from the Duke-NUS Medical School Class of 2026 and leaders from Duke-NUS, Duke University, NUS and SingHealth // Photo credit: Duke-NUS Medical School

The commencement ceremony, the first to be led by Dean Professor Patrick Tan, was attended by Guest of Honour Mdm Rahayu Mahzam, Minister of State for Digital Development and Information and for Health, and featured keynote remarks by Dr Robert Califf, who spoke about the extraordinary opportunities and upheavals now reshaping medicine, healthcare and biomedical science.

The Class of 2026 comprised 72 graduates from the MD programme, 6 MD-PhD graduates, 38 PhD graduates from Duke-NUS’ Integrated Biology and Medicine, Quantitative Biology and Medicine, and Clinical and Translational Sciences programmes, and 19 graduates from the Master’s in Patient Safety and Healthcare Quality. Among the MD graduands, there was an even split of 39 men and 39 women.

Another hallmark of Duke-NUS’ graduate-entry model is the breadth of experience its students bring into medicine. In the Class of 2026, that range includes graduates from engineering, product development, computer science, multimedia, business, accountancy, linguistics, psychology, history, communications, literature and the sciences.

A defining feature of Duke-NUS’ graduate-entry model is its emphasis on research. MD students devote their entire third year to research, and the Class of 2026 leaves behind a substantial body of published work across topics such as artificial intelligence in healthcare, predictive clinical tools, biological discovery, diagnostic innovation and population health. Together, the class produced 71 papers, including in journals such as Cell, The Lancet Microbe, Nature Communications, and npj Digital Medicine.

One of the standout papers, by MD-PhD graduate Charles Kevin Dee Tiu, described a rapid test that identified infection-blocking antibodies within hours to support Singapore’s COVID-19 response. Published in Nature Biotechnology, the paper has been cited 1,392 times.  

Dean Professor Patrick Tan said, “When the School was established, the aim was not simply to add another medical school to Singapore. It was to create something different by design: a graduate-entry medical school that brings together the strengths of Duke and NUS and is deeply embedded in Singapore’s healthcare system through SingHealth. That vision is reflected in this class. Our graduates bring intellectual range, a strong sense of service and the ability to think across disciplines at a time when medicine is being reshaped by science, technology and wider societal change.”

Community service also stood out strongly in the Class of 2026. Across their years at Duke-NUS, students took part in at least 14 community projects in Singapore and overseas.

These included school-readiness programmes for families, overseas medical missions to Nepal and Sri Lanka, Healthy-To-Thrive, a project which offers public health screening for chronic diseases for migrant workers, and community initiatives such as the Paediatric Solid Brain Tumour Awareness Day and Camp SIMBA, an annual camp for children whose loved ones are living with cancer.

Dr Jiang Qianfeng, graduating speaker of the MD Class of 2026 and recipient of both the Ngee Ann Kongsi Distinguished Scholars Programme and the Mount Elizabeth-Gleneagles Graduate Scholarship, said, “Our Class of 2026 demonstrated a deep commitment to service across diverse communities, from rural outreach programmes in Nepal and Sri Lanka, to local initiatives supporting children with brain tumours, migrant workers, community health and women’s health. These experiences reminded us that medicine doesn’t start and end within hospital walls and they strengthened our commitment to serve wherever the need is greatest.”

Among the initiatives shaped during the class’s time at Duke-NUS was Project WISE (Women’s Integrated Screening & Education), a programme that provides women with blood pressure and body mass index screenings, alongside education on mental health and breast cancer awareness. It is organised by the Women in Medicine student interest group, founded by MD graduand Dr Chan Kai Lin, and supported by the Association of Women Doctors (Singapore).

As Patrick Tan’s first graduating class as Dean, the Class of 2026 signals where Duke-NUS is headed: educating doctors and scientists who not only have their strengths in clinical practice, but are also able to work across research, innovation, technology and broader challenges shaping health today.

About Duke-NUS Medical School

Duke-NUS is Singapore’s flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.   

For more information, please visit www.duke-nus.edu.sg 

Shaping the Future Together! What Global Guests Said at the 2026 China-CEEC Local Leaders’ Meeting and Shandong Friendship Cities Week

JINAN, China, May 30, 2026 /PRNewswire/ — From May 25 to 29, 2026, the 7th China–CEEC Local Leaders’ Meeting and 2026 Shandong International Friendship Cities Cooperation and Exchange Week, hosted by Shandong Provincial People’s Government, the Secretariat of Cooperation between China and Central and Eastern European Countries, and China-CEEC Association of Provincial Governors, was successfully held. More than 600 Chinese and international guests from 44 countries and 15 provinces, autonomous regions and municipalities across China gathered in Shandong to advance cooperation, share opportunities and shape the future together.


Unlocking Friendly cooperation Keywords

Which countries did the guests come from? What were their impressions of Shandong? And what areas of exploration and cooperation brought them to the event? Reporters from the Shandong International Communication Center spoke with international guests in a rapid-fire Q&A, highlighting key words in Shandong’s friendship city cooperation with Central and Eastern Europe.

Five Survivors Rescued from Xaysomboun Cave, Search Continues

Five survivors rescued in the Xaysomboun cave rescue operation, but the mission is still continuing. May . (Photo credit: เก่งกาจ บ้งกาวงศ์)

Five villagers trapped inside a flooded cave in Xaysomboun province have now been brought out alive in a major breakthrough in a rescue operation that has entered its tenth day.

Four survivors emerged from the cave at 3:10 PM on 30 May. 

They were escorted safely out of the cave with help from emergency crews. Their rescue follows the successful extraction of another survivor on 29 May. 

On 30 May, additional cave diving experts arrived at the site to help rescue teams assess conditions inside the cave and identify strategies to locate and reach the two villagers still trapped inside the cave.

Working alongside Lao authorities, rescue teams have been pumping water out of the cave to improve water flow and lower water levels more quickly.

Thai rescue team leader Kengkat Bongkawong reported that teams have also surveyed nearby reservoirs, waterways, and mining areas in search of additional drainage routes.

At 4:47 p.m. a Thai rescue volunteer reported rain returned to the area on 30 May, raising concerns that rising water levels could further complicate rescue efforts.

Operations will continue.

MakerWorld’s First User-Initiated Charity Contest Names Winners, Bringing Global Creators’ Goodwill Directly to Cancer Wards

AUGSBURG, Germany, May 30, 2026 /PRNewswire/ — MakerWorld’s first user-initiated charity design contest has completed: winners have now been selected from 2,056 models submitted by 1,008 creators worldwide. Created in support of the Pieksekisten project, the contest drew more than 250,000 unique visitors and is helping turn digital designs, platform points, and community goodwill into 3D-printed gifts for children in cancer wards.

1 of the Batches Sent to Hospital
1 of the Batches Sent to Hospital

From a Personal Journey to a Shared Mission

Pieksekisten, literally “comfort boxes” in German, are small boxes filled with gifts for children who have just undergone treatment, examinations, or stressful hospital appointments. They are not grand presents, but they can offer something kind in a difficult moment. After a shot or a blood draw, a small object a child gets to choose for themselves can mean everything.

The project began in February 2023, in the day clinic of the Augsburg Pediatric Oncology Center, where Pascal Neumann’s son Thore was being treated for Grade IV medulloblastoma, an aggressive pediatric brain tumor. Pascal’s partner Silke began asking how small positive moments could be created for children on the ward, after a defining instance one day: a song played on the radio after Thore’s MRI examination, and it became achingly clear how exhausting clinical routine truly is for young children, not only medically, but emotionally.

The first Pieksekisten arrived at the clinic in March 2023, filled with classic small gifts. 3D printing was added later, when Pascal noticed something his son did with the rough early prints from his beginner-level 3D printer:

“For me, it was a failed print. For him, it was something his father had made for him. He was happy about things I myself would have thrown away long before.”

Thore passed away in October 2023, at just five years old.

The project is carried today by Pascal and Silke together, with a clear division of work: Silke coordinates with the hospital ward, including appointments, on-site handovers, direct communication with clinical staff, and Instagram documentation, while Pascal handles the technical infrastructure, including the website, MakerWorld and Bambu Lab communications, model curation, and printing. Early on, the pediatric clinic acknowledged the project in an official letter of thanks, explicitly recognizing the real-world effect of these small positive moments on children during difficult treatments. The hospital and pediatric oncology context is included here as the personal and real-world background that inspired and shaped the project, not as a statement of formal institutional hospital involvement or official partnership.

As word spread through the MakerWorld community, a platform where 2 million users share, remix, and download models daily, designers began spontaneously contributing models. Even before any formal contest, Pascal had documented permissions from more than 50 designers, secured one by one through forum messages and direct conversations. The growing enthusiasm caught the attention of the MakerWorld team, who reached out to Pascal to formalize what was already happening organically.

“MakerWorld was the first place where all of this came together: people already designing exactly the right kinds of things, an active printing community, real practical feasibility, and a platform where an idea could very quickly become something tangible and useful.” — Pascal

Why Not Just Mail Toys? — A Controlled Pipeline of Goodwill

Every model that enters a Pieksekiste begins as a file on a creator’s workstation, often on the other side of the world. A designer uploads a file to MakerWorld. Pascal clicks download. Seconds later, the file is on his printer, building layer by layer. It’s like sending a fax, but what’s transmitted isn’t text; it’s warmth you can hold in your hand.

International shipping of a physical toy typically costs $20–50 per parcel and takes 2–6 weeks, plus customs forms. The same care, sent as a file and printed locally? Within a day. Less than a dollar. Nearly zero carbon footprint.

On MakerWorld, models are designed to work seamlessly with Bambu Lab printers, and many come with ready-to-use print profiles. Pascal currently runs three Bambu Lab P1S Combo systems, identical units expanded over time for reliability, achieving a 98% usable production rate in daily operation.

These are not items pulled from a warehouse shelf. As Pascal puts it, they are consciously made, with time, attention, and the thought of giving one child a small positive moment. What children pick first on the ward, what gets handled most often, and what staff see working in practice feeds directly back into the next round of model selection, creating a closed loop between bedside reality and production planning.

And the designs themselves remain freely available. Anyone can download and print their own version, imagining it now in the hands of another child fighting their own battle somewhere in the world.

But controlled goodwill is not only about logistics. It is also about how a gift reaches a child. The Pieksekisten are not open toy boxes. They are placed at specific points within the treatment workflow — the finger-prick room and examination rooms 3 and 5 — and used only under nurse supervision. After a procedure, a child chooses one small object for themselves, with staff present.

“The boxes are a deliberately placed and controlled point of handover within everyday clinical life,” Pascal explains. “Not an open toy offering.”

This level of control is medical, not organizational. Many of the children on the ward are severely immunocompromised. For now, Pascal accepts no externally printed finished pieces, only digital files transformed into physical objects through his own equipment, on PLA filament, with every print visually inspected before it leaves his hands.

“As soon as material quality, production quality, or safety can no longer be reliably verified, the sustainability of the project itself would immediately be at risk.”

A Charity Contest That Broke New Ground

On April 2, 2026, MakerWorld launched the Pieksekisten Design Contest, the platform’s first charity contest, co-developed by a community member in partnership with MakerWorld. While the contest page was formally “Hosted By U: @JamesDaRock,” the initiative grew from a true meeting of minds: designers had already been contributing for weeks, and the MakerWorld team built the contest framework together with Pascal to give that goodwill a proper home.

Within three weeks, 1,008 creators submitted 2,056 distinct models, with the contest page drawing more than 250,000 unique visitors. Before the contest, the project had run on permissions from roughly 50 designers, gathered one by one over many months through Bambu Lab forum messages and direct conversations. In three weeks, that creative pool expanded roughly 40-fold. Today, about half of the documented production batches in active circulation already trace back to contest submissions.

Each submission was reviewed by Pascal for safety, child-appropriateness, and print reliability. Throughout, he applied the same standard he had used from day one: no model enters a Pieksekiste without clear, documented permission from its designer.

“A model is not just a file. It is the time, experience, and creative work of a person — and that is exactly how it should be treated.”

“Just because you can print something does not automatically mean you should simply take it.”

Winners Announced

The top three winning designs reflect the practical and emotional range of the brief:

  • 1st Place: Wall Decor & IV Stand Clip Pieksekisten x Art Zig by @La Forge d’Orion
  • 2nd Place: Puppet Theater with Puppets and Scenery by @berri3D
  • 3rd Place: Brain Teaser Puzzle Board | 48 Challenges | 5 Levels by @PrecisionCrafts

The Community Favorite award went to Pieksi – A friend from a syringe @DIY Wizard.

The Kids Choice selection is still underway. Finalists will be introduced to children in the ward, and the designs that spark the greatest smiles will be announced publicly on the MakerWorld contest page once the children’s voting process is complete.

“Every model submitted carried someone’s time, care, and imagination, and many of them will continue to be reviewed, printed, and tested in the real everyday life of the ward. To everyone who contributed: thank you for helping us create more of those moments.”

— Pascal Neumann

Points Donation — Converting Earned Credit into Bedside Gifts

Throughout the competition, participants repeatedly asked whether they could help beyond submitting models. The community itself surfaced the answer: could there be a way to donate points directly to support Pascal? Just three days later, on April 30, MakerWorld launched its first charitable Points Donation feature. On day one alone, 8,000 points were raised.

As of May 26, 555 contributors have donated 102,622 points, that represents about more than $8,300 in platform credit — enough to redeem more than 400 rolls of PLA Basic filament, or approximately 13 units of P2S. The donation pool remains open until June 1, 2026.

Donated points will be converted directly into filament, printers, and production resources, with MakerWorld facilitating delivery to Pascal. Three P1S printers currently sustain the two-week production-to-clinic cadence and are running near full capacity. As donated points convert into additional equipment and materials, that cadence is expected to accelerate meaningfully, keeping pace with growing internal demand: the Augsburg puncture rooms, the Stupfzimmer, have recently requested their own dedicated 3D boxes.

MakerWorld’s Role — Infrastructure the Community Could Use

For MakerWorld, what’s worth sharing here is not only goodwill itself, but what existing platform infrastructure made possible once a member-led cause found a clear workflow. The contest used MakerWorld’s standard competition framework, adapted with Pascal into the platform’s first charity design contest. When the community asked how to do more, the first Points Donation feature shipped within days, turning a recurring forum question into a productized support path. The same systems that normally reward creators for downloads and community activity became a bridge from digital credit to bedside hardware, without Pascal building custom tooling or running parallel logistics.

How to Be Part of This

Looking Ahead

On June 1, MakerWorld will formally close the Pieksekisten Points Donation pool. After the campaign ends, MakerWorld will publish a follow-up impact report summarizing final donation totals, converted materials, and project delivery progress.

Pascal is deliberately cautious about scaling beyond Augsburg.

“Pediatric oncology wards are protected for very good reasons — and they should be. The real bottleneck is access, not production. The goal is first to build a model that works reliably here, and only then to consider whether it could responsibly be transferred elsewhere.” — Pascal

“This project showed us something we’d never seen before: a charity that runs on creativity instead of logistics. Designers contributed from São Paulo, Berlin, and beyond — and their gifts printed themselves across the world. We’re proud to have built the infrastructure that lets a community’s care travel directly from a designer’s screen to a child’s hand.”

—Qianye, Creator Operation of MakerWorld

About MakerWorld

MakerWorld is the world’s largest 3D model sharing, downloading, and printing community, operated by Bambu Lab. With over 2 million free models and thousands of new designs added daily, MakerWorld is accessible directly through its website or via Bambu software such as Bambu Studio, championing a mission of community-driven, technology-for-good. Learn more at makerworld.com

About Bambu Lab

Bambu Lab is a consumer-tech company focusing on desktop 3D printers. Its state-of-the-art 3D printers offer a feature-rich first-class experience for a global community of 3D printing makers, aiming to break the barriers between the digital and physical worlds and bring creativity to a whole new level. Bambu Lab sells its 3D printers, filaments, and accessories on its official website, serving customers across 30+ countries.

Learn more at Bambu Lab Official Website

For those who wish to explore further

Printing: Brain Teaser Puzzle Board by @PrecisionCrafts
Printing: Brain Teaser Puzzle Board by @PrecisionCrafts

1st Place: Wall Decor & IV Stand Clip Pieksekisten x Art Zig by @La Forge d'Orion
1st Place: Wall Decor & IV Stand Clip Pieksekisten x Art Zig by @La Forge d’Orion

Processing the Printed Items
Processing the Printed Items

Points Donation on MakerWorld
Points Donation on MakerWorld

ENERtec Asia 2026 Partners with MIDA to Power Malaysia’s Digital Economy via Renewable Energy and Battery Storage Innovation

Strategic collaboration positions Malaysia as a regional clean energy investment hub amid surging AI and data centre power demand

KUALA LUMPUR, Malaysia, May 30, 2026 /PRNewswire/ — As shifting geopolitical dynamics, regional supply chain realignments, and surging electricity demand reshape global trade, Malaysia is intensifying efforts to strengthen energy security and future-proof its economic growth through renewable energy (RE) and battery energy storage systems (BESS).

ENERtec Asia 2026 - The Energy Gathering of the Region
ENERtec Asia 2026 – The Energy Gathering of the Region

In a strategic move to address these evolving priorities, ENERtec Asia 2026, Southeast Asia’s premier energy technology exhibition and conference, has announced a landmark collaboration with the Malaysian Investment Development Authority (MIDA). This partnership underscores the pivotal role that clean energy and intelligent storage infrastructure play in anchoring Malaysia’s rapidly expanding digital economy.

Co-located with The Energy Transition Conference (ETCon) by Tenaga Nasional Berhad (TNB) under the unified theme “Energy & AI: The Synergy for Energy Transition,” ENERtec Asia 2026 will take place from 3 to 5 June 2026 at the Kuala Lumpur Convention Centre (KLCC). The platform will explore how the convergence of artificial intelligence, RE, power grid and advanced storage technologies is reshaping industrial operations, infrastructure planning, and sustainable economic development across ASEAN.

As Malaysia continues to attract high-value investments in artificial intelligence (AI), hyperscale data centres, cloud computing, and advanced manufacturing, the strain on the national grid is set to rise sharply. Against this backdrop, renewable energy and battery storage are no longer viewed merely as sustainability goals but as critical economic infrastructure required to ensure grid reliability, operational continuity, and long-term industrial competitiveness.

MIDA’s role as Strategic Partner reflects broader national efforts to strengthen Malaysia’s clean energy investment ecosystem and accelerate diversification of the country’s energy mix. The collaboration directly aligns with the country’s aspirations to position itself as the preferred regional destination for next-generation energy technologies and sustainable industrial development.

Datuk Sikh Shamsul Ibrahim Sikh Abdul Majid, CEO of MIDA, said, “MIDA is thrilled to stand alongside ENERtec Asia 2026 as a strategic partner for the second time. This year’s theme perfectly captures the trajectory of Malaysia’s industrial transformation. By leveraging AI to revolutionise our energy infrastructure, we can fast-track our net-zero goals. The explosion of the digital economy brings unique challenges and massive opportunities, solidifying Malaysia’s position as a premier regional hub for green energy and sustainable technology. By bridging private sector innovation with government facilitation, we are translating green ambitions into actionable, investment-ready opportunities that will drive sustainable economic growth for both local and international investors.”

“Renewable energy and intelligent energy storage are no longer future considerations. They are the fundamental pillars supporting economic resilience, digital expansion, and investment competitiveness today,” said Tan Sri Abdul Rahman Mamat, Chairman of Informa Markets Malaysia.

“In an increasingly complex global environment, energy diversification is vital for economic stability. Our collaboration with MIDA reflects a shared commitment to building a future-ready energy ecosystem capable of powering Malaysia’s industrial transformation.”

Organised by Informa Markets Malaysia and co-hosted by The Electrical and Electronics Association of Malaysia (TEEAM), the joint powerhouse event is expected to draw more than 12,000 industry professionals from 60 countries and regions, alongside 1,000 companies and brands across seven exhibition halls. The event is officially endorsed by the Malaysia External Trade Development Corporation (MATRADE) and the Global Association of the Exhibition Industry (UFI), with the Energy Commission of Sabah serving as a strategic partner.

A central highlight of the event is WATT’S NEXT, a flagship seminar and workshop designed to address Southeast Asia’s evolving energy landscape through two strategic, interconnected pillars:

  • Energy & AI: Addressing the high power demands of AI infrastructure (Energy for AI) and using machine learning to maximise grid efficiency (AI for Energy).
  • Renewable Energy & BESS: Showcasing utility-scale battery storage and clean energy solutions critical for grid stability and peak load management.

As part of this high-level dialogue, MIDA will lead a dedicated session focusing on emerging growth sectors, public-private investment frameworks, and capital deployment opportunities within Malaysia’s National Energy Transition Roadmap (NETR).

On the exhibition floor, global and regional market leaders will showcase the latest advancements in smart grids, EV infrastructure, and energy efficiency. Prominent participating brands include ABB, Eaton, Leoch Battery, Samaiden, Legrand, Fluke, ERS Energy, IEP, Smart Cable, and United ULi Corporation Berhad.

The event also welcomes global battery giant CATL as the Official Energy Transition & Intelligent Storage Partner, alongside key corporate sponsors including Hasilwan, Hithium, PEKAT Group Berhad, Icents Group Holdings Berhad, and Glocomp Systems.

To maximise industry participation, the event will launch the SPOT ENERtec Asia Campaign, a high-impact mix of Klang Valley outdoor advertising, targeted digital activations, and on-ground engagement. Registered trade visitors who interact with the campaign can redeem exclusive limited-edition merchandise during the exhibition.

ENERtec Asia 2026 is actively supported by the Malaysia Convention & Exhibition Bureau (MyCEB) alongside influential industry bodies, including the Asia Pacific Urban Energy Association (APUEA), Association of Consulting Engineers Malaysia (ACEM), Data Centre Industry Association (DCIA), Malaysia Association of Energy Service Companies (MAESCO), Malaysia Carbon Market Association (MCMA), Malaysian Photovoltaic and Sustainable Energy Industry Association (MPSEA), and Singapore Battery Consortium.

As Southeast Asia accelerates its transition toward decarbonisation, electrification, and digitalisation, ENERtec Asia remains a definitive strategic platform connecting policymakers, investors, technology providers, and industry leaders to shape the region’s sustainable energy future.

Industry professionals, investors, and corporate decision-makers are encouraged to pre-register online to secure their access to the exhibition and high-level conference tracks. For more information and full event details, visit https://www.enertecasia.com/

END

Notes to Editors

About ENERtec Asia

ENERtec Asia is ASEAN’s leading energy technology exhibition, organised by Informa Markets and co-hosted by The Electrical and Electronics Association of Malaysia (TEEAM). The event brings together solution providers, technology innovators, investors, and industry leaders to showcase next-generation energy solutions across renewable energy, grid modernisation, industrial energy efficiency, decarbonisation, and AI-enabled technologies. ENERtec Asia provides a platform for knowledge exchange, business development, and real-world deployment, accelerating sustainable and resilient energy transition across Southeast Asia. For more information, visit www.enertecasia.com.

About MIDA

The Malaysian Investment Development Authority (MIDA) is the Government’s principal investment promotion and development agency under the Ministry of Investment, Trade and Industry (MITI) to oversee and drive investments into the manufacturing and services sectors in Malaysia. Headquartered in Kuala Lumpur Sentral, MIDA has 12 regional and 20 overseas offices. MIDA continues to be the strategic partner to businesses in seizing the opportunities arising from the technology revolution of this era. For more information, please visit www.mida.gov.my and follow us on X, Instagram, Facebook, LinkedIn, TikTok and YouTube channel.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate, and grow. Our portfolio comprises more than 450 international B2B events and brands in markets including Healthcare C Pharmaceuticals, Infrastructure, Construction C Real Estate, Fashion C Apparel, Hospitality, Food C Beverage, and Health C Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience, and do business through face-to-face exhibitions, specialist digital content, and actionable data solutions. For more information, visit www.informamarkets.com.

About Tenaga Nasional Berhad (TNB)

Tenaga Nasional Berhad (TNB) is Malaysia’s leading electricity utility and the largest publicly listed power company in Southeast Asia. Guided by its Energy Transition Plan and a commitment to achieve Net Zero emissions by 2050, TNB is advancing a “Grid of the Future” to support Malaysia’s digital and low-carbon economy. Through the integration of large-scale renewable energy, smart grid technologies, and EV infrastructure, TNB continues to power national and regional growth while driving the synergy between energy and artificial intelligence. For more information, visit www.tnb.com.my.